Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) announced that it has completed the construction of an extensive library of full-length, fully human monoclonal antibodies (mAbs). Initial analysis indicates a potential diversity of more than one trillion unique mAbs. The company believes this makes its library the largest full-length, fully human antibody library available for drug discovery and development partnerships... 
More...
More...